Dbv Technologies S.A. Sponsored ADR (DBVT)
NASDAQ (CM) NASDAQ (CM) Primary Summary
DBVT Chart
DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old
Châtillon, France, June 25, 2025 DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old First subject screened at the Respiratory Medicine Research Institute of Michigan with Dr. Jeffrey Leflein acting as Principal Investigator Additional sites, including Allergy and Asthma Center of Minnesota and Hamilton Allergy and Immunology Clinic of Ontario, Canada have been activated and are scheduling screenings DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), a clinical-stage biopharmaceutical company, today provided an update on the progress on the Company's COMFORT Toddlers supplemental safety study using the Viaskin® Peanut patch 250 μg in peanut-allergic children ages 1 – 3 years old. COMFORT Toddlers will enroll approximately 480 subjects at approximately 80 – 90 study centers across the U.S., Canada, Australia, UK and Europe.
DBV Technologies to Participate in Upcoming EAACI Congress 2025
Châtillon, France, June 12, 2025 DBV Technologies to Participate in Upcoming EAACI Congress 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 13 – 16, 2025, in Glasgow, United Kingdom. DBV will present two posters and will also host a symposium and exhibit booth in the EAACI exhibit hall.
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting
Châtillon, France, June 11, 2025 DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen, Chairman of the Company.
Dbv Technologies S.A. Sponsored ADR Dividends
Dbv Technologies S.A. Sponsored ADR Earnings
| 5 Mar 2025 Date | | - Cons. EPS | - EPS |
| 29 Jul 2024 Date | | - Cons. EPS | - EPS |
| 16 May 2024 Date | | - Cons. EPS | - EPS |
| 9 May 2024 Date | | - Cons. EPS | - EPS |
| 2 May 2024 Date | | - Cons. EPS | - EPS |
| 5 Mar 2025 Date | | - Cons. EPS | - EPS |
| 29 Jul 2024 Date | | - Cons. EPS | - EPS |
| 16 May 2024 Date | | - Cons. EPS | - EPS |
| 9 May 2024 Date | | - Cons. EPS | - EPS |
| 2 May 2024 Date | | - Cons. EPS | - EPS |
Dbv Technologies S.A. Sponsored ADR (DBVT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Dbv Technologies S.A. Sponsored ADR ever had a stock split?
Dbv Technologies S.A. Sponsored ADR Profile
| Biotechnology Industry | Healthcare Sector | Daniel Tassé CEO | NASDAQ (CM) Exchange | 23306J101 Cusip |
| FR Country | 106 Employees | - Last Dividend | 7 Jun 2024 Last Split | 22 Oct 2014 IPO Date |
Overview
DBV Technologies S.A. is a clinical-stage biopharmaceutical company established in 2002, with its headquarters located in Montrouge, France. The company is at the forefront of developing epicutaneous immunotherapy (EPIT) products, aimed at the research and development in the realm of allergies and immune-related diseases. It is dedicated to improving the lives of patients suffering from food allergies and other immunological diseases by leveraging its innovative Viaskin technology platform. This approach underscores DBV Technologies’ commitment to advancing healthcare through research, reflecting its status as a pioneer in the field of immunotherapy.
Products and Services
- Viaskin Peanut
- Viaskin Milk
- Vaccine Research Programs
- MAG1C for CMPA Diagnosis
Viaskin Peanut stands as a flagship product from DBV Technologies, crafted as an immunotherapy solution for peanut allergies. Having progressed through a Phase 3 clinical trial, Viaskin Peanut epitomizes the company’s dedication to offering innovative treatments. It employs the novel approach of epicutaneous delivery, wherein the therapy is administered through a patch that is placed on the skin. This method is designed to potentially desensitize individuals to peanut allergens, offering hope to many who are affected by this prevalent allergy.
Currently in a Phase 1/2 clinical trial, Viaskin Milk is DBV Technologies' venture into addressing cow's milk protein allergy and eosinophilic esophagitis, conditions predominantly associated with immunoglobulin E (IgE) mediation. This investigational product extends the use of the company’s patented epicutaneous immunotherapy platform, aiming to alleviate symptoms associated with milk allergies. By tackling such a common food allergy, Viaskin Milk signifies a major step forward in the global fight against allergic diseases.
The company is also venturing into earlier stage research, which includes the development of a vaccination for the respiratory syncytial virus, alongside potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. These programs signal DBV Technologies’ broader objective to harness and expand the applicability of its Viaskin technology beyond food allergies, targeting a wider array of immune-mediated conditions.
In collaboration with Nestlé Health Science, DBV Technologies is working on MAG1C, a novel atopy patch test designed for the diagnosis of non-IgE mediated cow's milk protein allergy (CMPA) in infants and toddlers. MAG1C represents an innovative diagnostic approach, potentially simplifying and improving the accuracy of diagnosing CMPA, which is often challenging. This partnership underscores the company's commitment to not only treating but also aiding in the accurate diagnosis of allergies.
Contact Information
